



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ramucirumab

Cat. No.:	HY-P9920
CAS No.:	947687-13-0
Molecular Formula:	C <sub>6374</sub> H <sub>9864</sub> N <sub>1692</sub> O <sub>1996</sub> S <sub>46</sub>
Molecular Weight:	143609.62
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder    -20°C    3 years 4°C        2 years In solvent   -80°C    2 years -20°C    1 year

### BIOLOGICAL ACTIVITY

Description	Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	VEGFR-2
In Vitro	Ramucirumab (10 µg/mL) impedes both VEGF- and tumor-driven cord formation <sup>[3]</sup> . ?Ramucirumab does not cross react with mouse VEGFR2 <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- ACS Appl Mater Interfaces. 2023 Feb 14.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. *Oncotarget*. 2019 Sep 17;10(53):5523-5533.
- [2]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. *Am Health Drug Benefits*. 2015 Mar;8(Spec Feature):49-53.
- [3]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. *J Adv Pract Oncol*. 2015 Jan-Feb;6(1):71-5.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA